ArticleFrontiers in pharmacology2026
Enhancing the rational use of sodium valproate in neurosurgery: a pharmacist-led PDCA intervention.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Inappropriate use of sodium valproate (VPA) for seizure prophylaxis in neurosurgery poses clinical risks and increases healthcare costs. This study aimed to evaluate the effectiveness of a clinical pharmacist-led intervention, integrated with the Plan-Do-Check-Act (PDCA) cycle, in optimizing VPA utilization among neurosurgical patients. Methods: This retrospective pre-post study analyzed patients in the Neurosurgery Department of a tertiary hospital who received sodium valproate between July 2022 and December 2024. A multidisciplinary team, led by clinical pharmacists, implemented a PDCA cycle to standardize sodium valproate administration. Key metrics-including irrational drug use, treatment duration, and Defined Daily Doses (DDDs)-were compared pre- and post-implementation. Results: The intervention significantly increased the rational use of sodium valproate from 32.00% to 93.41%. This clinical shift was accompanied by substantial resource optimization, including a reduction in the average duration of injectable therapy (from 8.32 ± 6.44 to 5.37 ± 3.81 days) and a dramatic decline in the DDDs of prophylactic intravenous sodium valproate (from 184.69 ± 50.40 to 17.91 ± 8.92). Furthermore, inappropriate average DDDs were reduced from 0.55 ± 0.22 to 0.17 ± 0.09. Conclusion: A pharmacist-led PDCA cycle is a feasible and highly effective strategy for fostering the rational use of sodium valproate in neurosurgical settings. These findings highlight the value of multidisciplinary frameworks in enhancing medication safety and institutional resource management within complex clinical environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.